The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | The importance of TP53 in CLL
In this video, Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, comments on the important role of TP53 in chronic lymphocytic leukemia (CLL), emphasizing its function as a tumor suppressor gene. Dr Rosenquist also explains how TP53 aberrations play a role in patient response to therapy and the growing importance of BTK inhibitors and BCL2 inhibitors as a treatment option for these patients. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
